Abstract
The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.
| Original language | English |
|---|---|
| Pages (from-to) | 3265-3275 |
| Journal | Expert opinion on pharmacotherapy |
| Volume | 8 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - 26 Nov 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Highlights, Institutes and Platforms
- Manchester Cancer Research Centre
Fingerprint
Dive into the research topics of 'Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver